01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Comparative Effectiveness and Safety of a Catheterization Laboratory–Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention

Hitinder S. Gurm, MD, Carrie Hosman, PhD, Eric R. Bates, MD, David Share, MD and Ben B. Hansen, PhD; for the Blue Cross Blue Shield of Michigan Cardiovascular Consortium

Background: Eptifibatide, a small-molecule glycoprotein IIb/IIIa inhibitor, is conventionally administered as a bolus plus infusion. A growing number of clinicians are using a strategy of catheterization laboratory–only eptifibatide (an off-label use) as procedural pharmacotherapy for patients undergoing percutaneous coronary intervention although the comparative effectiveness of this approach is unknown.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Congenital Heart Disease. Percutaneous Pulmonary Valve Implantation: 5 Years of Follow-Up Does Age Influence Outcomes?

Sharon Borik, MD, Andrew Crean, MD, FRCPC, Eric Horlick, MDCM, FRCPC, Mark Osten, MD, FRCPC, Kyong-Jin Lee, MD, FRCPC, Rajiv Chaturvedi, MD, PhD, MRCP(UK), Mark K. Friedberg, MD, Brian W. McCrindle, MD, FRCPC, Cedric Manlhiot, BSc and Lee Benson, MD, FRCPC

Background: Percutaneous pulmonary valve implantation (PPVI) is a safe, less invasive alternative to surgical valve replacement for the congenital heart disease patient with right ventricular (RV) outflow tract dysfunction. The aim of this study was to determine whether reverse RV remodeling after PPVI was persistent in the longer term and whether timing of PPVI influenced outcomes.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. Meta-Analysis of 4992 Patients

Giuseppe Gargiulo, MD, Davide Capodanno, MD, PhD, Anna Sannino, MD, Cinzia Perrino, MD, PhD, Piera Capranzano, MD, Eugenio Stabile, MD, Bruno Trimarco, MD, Corrado Tamburino, MD, PhD and Giovanni Esposito, MD, PhD

Background: There is a conflicting evidence on safety and efficacy of transcatheter aortic valve implantation in patients with preoperative chronic kidney disease (CKD). Therefore, we conducted a meta-analysis on the impact of CKD on outcomes after transcatheter aortic valve implantation.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Impact of Mitral Regurgitation on Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation

Crochan J. O’Sullivan, MD*, Stefan Stortecky, MD*, Anne Bütikofer, MD, Dik Heg, PhD, Thomas Zanchin, MD, Christoph Huber, MD, Thomas Pilgrim, MD, Fabien Praz, MD, Lutz Buellesfeld, MD, Ahmed A. Khattab, MD, Stefan Blöchlinger, MD, Thierry Carrel, MD, Bernhard Meier, MD, Stephan Zbinden, MD, Peter Wenaweser, MD and Stephan Windecker, MD*

Background: Up to 1 in 6 patients undergoing transcatheter aortic valve implantation (TAVI) present with low-ejection fraction, low-gradient (LEF-LG) severe aortic stenosis and concomitant relevant mitral regurgitation (MR) is present in 30% to 55% of these patients. The effect of MR on clinical outcomes of LEF-LG patients undergoing TAVI is unknown.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Physiologic Assessment and Imaging. Optical Coherence Tomographic Observation of In-Stent Neoatherosclerosis in Lesions With More Than 50% Neointimal Area Stenosis After Second-Generation Drug-Eluting Stent Implantation

Seung-Yul Lee, MD*, Seung-Ho Hur, MD*, Sang-Gon Lee, MD, Sang-Wook Kim, MD, Dong-Ho Shin, MD, MPH, Jung-Sun Kim, MD, Byeong-Keuk Kim, MD, Young-Guk Ko, MD, Donghoon Choi, MD, Yangsoo Jang, MD and Myeong-Ki Hong, MD

Background: Despite the enhanced properties of the second-generation drug-eluting stent (DES), its association with neoatherosclerosis has not been sufficiently evaluated. Therefore, we sought to evaluate and compare neoatherosclerosis in second-generation DESs to first-generation DESs.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction. Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Guido Parodi, MD, PhD, Benedetta Bellandi, MD, Ioanna Xanthopoulou, MD, Piera Capranzano, MD, Davide Capodanno, MD, PhD, Renato Valenti, MD, Katerina Stavrou, MD, Angela Migliorini, MD, David Antoniucci, MD, Corrado Tamburino, MD and Dimitrios Alexopoulos, MD

Background: Morphine is recommended in patients with ST-segment–elevation myocardial infarction, including those undergoing primary percutaneous coronary intervention. Suboptimal antiplatelet effect during and after primary percutaneous coronary intervention is associated with increased thrombotic complications. It was hypothesized a potential drug–drug interaction between morphine and antiplatelet agents. We sought to assess platelet inhibition after a loading dose of the currently recommended antiplatelet agents in ST-segment–elevation myocardial infarction patients according to morphine use.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Evaluation of Renal Function Before and After Percutaneous Mitral Valve Repair

Andrew Wang, MD, Chithra Sangli, MS, Scott Lim, MD, Gorav Ailawadi, MD, Saibal Kar, MD, Howard C. Herrmann, MD, Paul Grayburn, MD, Elyse Foster, MD, Neil J. Weissman, MD, Donald Glower, MD and Ted Feldman, MD

Background: Chronic kidney disease (CKD) is strongly related to outcome in cardiovascular diseases. The relationship between treatment of mitral regurgitation (MR) and renal function is not well described. We sought to evaluate renal function before and after mitral valve repair by the MitraClip device.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Percutaneous Treatment of Adult Isthmic Aortic Coarctation. Acute and Long-Term Clinical and Imaging Outcome With a Self-Expandable Uncovered Nitinol Stent

Stephan Kische, MD, PhD*, Giuseppe D’Ancona, MD, PhD*, Yannik Stoeckicht, MD, Jasmin Ortak, MD, PhD, Albrecht Elsässer, MD, PhD and Hüseyin Ince, MD, PhD

Background: To present perioperative and long-term results of percutaneous treatment of adult isthmic coarctation of the aorta by means of a self-expandable closed-web uncovered nitinol stent (Sinus-XL, Optimed, Esslingen, Germany).

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Long-Term Results of Transapical Versus Transfemoral TAVI in a Real World Population of 1000 Patients With Severe Symptomatic Aortic Stenosis

Gerhard Schymik, MD, Alexander Würth, MD, Peter Bramlage, MD, Tanja Herbinger, MD, Martin Heimeshoff, MD, Lothar Pilz, MSc, Jan S. Schymik, MSc, Rainer Wondraschek, MD, Tim Süselbeck, MD, Jan Gerhardus, MD, Armin Luik, MD, Bernd-Dieter Gonska, MD, Herbert Posival, MD, Claus Schmitt, MD and Holger Schröfel, MD

Background: Transapical transcatheter aortic valve implantation is generally perceived to be associated with increased morbidity compared with transfemoral transcatheter aortic valve implantation. We aimed to compare access-related complications and survival using propensity score matching.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Artery Disease. Effect of Obesity on Coronary Atherosclerosis and Outcomes of Percutaneous Coronary Intervention. Grayscale and Virtual Histology Intravascular Ultrasound Substudy of Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents

Soo-Jin Kang, MD, PhD, Gary S. Mintz, MD, Bernhard Witzenbichler, MD, D. Christopher Metzger, MD, Michael J. Rinaldi, MD, Peter L. Duffy, MD, MMM, Giora Weisz, MD, Thomas D. Stuckey, MD, Bruce R. Brodie, MD, Takehisa Shimizu, MD, PhD, Ke Xu, PhD, Ajay J. Kirtane, MD, SM, Gregg W. Stone, MD and Akiko Maehara, MD

Background: Obesity is a cardiovascular risk factor, but the obesity paradox in patients undergoing percutaneous coronary intervention is poorly understood.

01 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Clinical Outcomes of Treatment by Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Patients With Chronic Kidney Disease Undergoing Index Revascularization in Ontario

William Chan, MBBS, PhD, Joan Ivanov, PhD, Dennis Ko, MD, Stephen Fremes, MD, Vivek Rao, MD, PhD, Sanjit Jolly, MD, Warren J. Cantor, MD, Shahar Lavi, MD, Christopher B. Overgaard, MD, MSc, Marc Ruel, MD, Jack V. Tu, MD, PhD and Vladimír Džavík, MD

Background: There is a paucity of data on the comparative effectiveness of percutaneous coronary intervention using contemporary drug-eluting stent (DES) compared with coronary artery bypass graft (CABG) surgery in patients with chronic kidney disease.

18 noviembre 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Spontaneous Coronary Artery Dissection. Revascularization Versus Conservative Therapy

Marysia S. Tweet, MD, Mackram F. Eleid, MD, Patricia J.M. Best, MD, Ryan J. Lennon, MS, Amir Lerman, MD, Charanjit S. Rihal, MD, MBA, David R. Holmes Jr, MD, Sharonne N. Hayes, MD and Rajiv Gulati, MD, PhD

Background: Spontaneous coronary artery dissection (SCAD) is a nonatherosclerotic acute coronary syndrome for which optimal management remains undefined.

18 noviembre 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model

Takashi Miyake, MD, PhD, Shinya Ihara, MSc, Tetsuo Miyake, MD, Yusuke Tsukada, BSc, Hajime Watanabe, BSc, Hiroaki Matsuda, BSc, Hideki Kiguchi, MSc, Hiroyuki Tsujimoto, PhD, Hironori Nakagami, MD, PhD and Ryuichi Morishita, MD, PhD

Background: Despite the advent of drug-eluting stents, restenosis after endovascular intervention is still a major limitation in the treatment of cardiovascular disease. To regulate the multiple biological mechanisms underlying restenosis, we focused on inhibition of an important transcription factor, nuclear factor-kappaB (NFκB), using a decoy strategy.

18 noviembre 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction. Relationship of the Distance Between Non-PCI Hospitals and Primary PCI Centers, Mode of Transport, and Reperfusion Time Among Ground and Air Interhospital Transfers Using NCDR’s ACTION Registry-GWTG

Benjamin D. Nicholson, BA, Harinder S. Dhindsa, MD, Matthew T. Roe, MD, Anita Y. Chen, MS, James G. Jollis, MD and Michael C. Kontos, MD

Background: ST-segment myocardial infarction patients frequently present to non-percutaneous coronary intervention (PCI) hospitals and require interhospital transfer for primary PCI. The effect of distance and mode of transport to the PCI center and the frequency that recommended primary PCI times are met are not clear.

28 octubre 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction. Intracoronary Delivery of Injectable Bioabsorbable Scaffold (IK-5001) to Treat Left Ventricular Remodeling After ST-Elevation Myocardial Infarction

Norbert Frey, MD, Axel Linke, MD, Tim Süselbeck, MD, Jochen Müller-Ehmsen, MD, Paul Vermeersch, MD, Danny Schoors, MD, Mark Rosenberg, MD, Florian Bea, MD, Shmuel Tuvia, PhD and Jonathan Leor, MD, FESC

Background: We aimed to test, for the first time, the feasibility of intracoronary delivery of an innovative, injectable bioabsorbable scaffold (IK-5001), to prevent or reverse adverse left ventricular remodeling and dysfunction in patients after ST-segment–elevation myocardial infarction.